{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:37:27Z","timestamp":1780627047570,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T00:00:00Z","timestamp":1487980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bayer Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s10072-017-2855-3","type":"journal-article","created":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T12:25:21Z","timestamp":1488025521000},"page":"745-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of rivaroxaban in patients with stroke"],"prefix":"10.1007","volume":"38","author":[{"given":"Danilo","family":"Toni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carolei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Del Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Inzitari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Provinciali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Santalucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Toso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,25]]},"reference":[{"key":"2855_CR1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"2855_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR et al (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11:315\u2013322","journal-title":"Lancet Neurol"},{"key":"2855_CR3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","volume":"124","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124:955\u2013962","journal-title":"Blood"},{"issue":"4","key":"2855_CR4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","volume":"17","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Ebetrtz F et al (2015) Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 17(4):530\u2013538","journal-title":"Europace"},{"key":"2855_CR5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","volume":"30","author":"F Lalibert\u00e9","year":"2014","unstructured":"Lalibert\u00e9 F, Cloutier M, Nelson WW et al (2014) Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 30:1317\u20131325","journal-title":"Curr Med Res Opin"},{"key":"2855_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","volume":"38","author":"S Tamayo","year":"2015","unstructured":"Tamayo S, Frank Peacock W, Patel M et al (2015) Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 38:63\u201368","journal-title":"Clin Cardiol"},{"issue":"14","key":"2855_CR7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"AJ Camm","year":"2016","unstructured":"Camm AJ, Amarenco P, Haas S et al (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37(14):1145\u20131153","journal-title":"Eur Heart J"},{"key":"2855_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","volume":"10","author":"E Perzborn","year":"2011","unstructured":"Perzborn E, Roehrig S, Straub A et al (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10:61\u201375","journal-title":"Nat Rev Drug Discov"},{"key":"2855_CR9","unstructured":"European Medicines Agency (2014) Xarelto Summary of Product Characteristics. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf\n                        \n                    . Accessed 15 May 2016"},{"key":"2855_CR10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76:455\u2013466","journal-title":"Br J Clin Pharmacol"},{"key":"2855_CR11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","volume":"51","author":"J Stampfuss","year":"2013","unstructured":"Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549\u2013561","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2855_CR12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","volume":"61","author":"D Kubitza","year":"2005","unstructured":"Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2013an oral, direct Factor Xa inhibitor\u2013after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873\u2013880","journal-title":"Eur J Clin Pharmacol"},{"key":"2855_CR13","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","volume":"24","author":"D Kubitza","year":"2008","unstructured":"Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24:2757\u20132765","journal-title":"Curr Med Res Opin"},{"key":"2855_CR14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","volume":"37","author":"C Weinz","year":"2009","unstructured":"Weinz C, Schwarz T, Kubitza D et al (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37:1056\u20131064","journal-title":"Drug Metab Dispos"},{"key":"2855_CR15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/00498250500250493","volume":"35","author":"C Weinz","year":"2005","unstructured":"Weinz C, Buetehorn U, Daehler H-P et al (2005) Pharmacokinetics of BAY 59-7939\u2013an oral, direct Factor Xa inhibitor\u2013in rats and dogs. Xenobiotica 35:891\u2013910","journal-title":"Xenobiotica"},{"key":"2855_CR16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12325-012-0040-x","volume":"29","author":"F Lalibert\u00e9","year":"2012","unstructured":"Lalibert\u00e9 F, Nelson WW, Lefebvre P et al (2012) Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 29:675\u2013690","journal-title":"Adv Ther"},{"key":"2855_CR17","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","volume":"35","author":"R Cappato","year":"2014","unstructured":"Cappato R, Ezekowitz MD, Klein AL et al (2014) Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35:3346\u20133355","journal-title":"Eur Heart J"},{"key":"2855_CR18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","volume":"125","author":"J Donz\u00e9","year":"2012","unstructured":"Donz\u00e9 J, Clair C, Hug B et al (2012) Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 125:773\u2013778","journal-title":"Am J Med"},{"key":"2855_CR19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","volume":"18","author":"P Kirchof","year":"2016","unstructured":"Kirchof P, Benussi S, Kotecha D et al (2016). ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609\u20131678","journal-title":"Europace"},{"key":"2855_CR20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","volume":"103","author":"MM Samama","year":"2010","unstructured":"Samama MM, Martinoli J-L, LeFlem L et al (2010) Assessment of laboratory assays to measure rivaroxaban\u2013an oral, direct factor Xa inhibitor. Thromb Haemost 103:815\u2013825","journal-title":"Thromb Haemost"},{"key":"2855_CR21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH12-03-0209","volume":"108","author":"AGG Turpie","year":"2012","unstructured":"Turpie AGG, Kreutz R, Llau J et al (2012) Management consensus guidance for the use of rivaroxaban\u2013an oral, direct factor Xa inhibitor. Thromb Haemost 108:876\u2013886","journal-title":"Thromb Haemost"},{"key":"2855_CR22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2010.04106.x","volume":"9","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9:226\u2013228","journal-title":"J Thromb Haemost"},{"key":"2855_CR23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","volume":"130","author":"J Douxfils","year":"2012","unstructured":"Douxfils J, Mullier F, Loosen C et al (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:956\u2013966","journal-title":"Thromb Res"},{"key":"2855_CR24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40265-013-0056-9","volume":"73","author":"NJ Carter","year":"2013","unstructured":"Carter NJ, Plosker GL (2013) Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs 73:715\u2013739","journal-title":"Drugs"},{"key":"2855_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MEJ.0000000000000322","author":"E Bernardi","year":"2015","unstructured":"Bernardi E, Carbone G, Dentali F (2015) How to manage patients on rivaroxaban in the emergency department: a statement of the Italian society of emergency medicine advisory board. Eur J Emerg Med. doi:\n                        10.1097\/MEJ.0000000000000322","journal-title":"Eur J Emerg Med"},{"key":"2855_CR26","doi-asserted-by":"crossref","first-page":"935474","DOI":"10.1155\/2014\/935474","volume":"2014","author":"J Koscielny","year":"2014","unstructured":"Koscielny J, Rutkauskaite E (2014) Rivaroxaban and hemostasis in emergency care. Emerg Med Int 2014:935474","journal-title":"Emerg Med Int"},{"key":"2855_CR27","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","volume":"6","author":"S Kralev","year":"2011","unstructured":"Kralev S, Schneider K, Lang S et al (2011) Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 6:e24964","journal-title":"PLoS One"},{"key":"2855_CR28","first-page":"33","volume":"9","author":"M Mirra","year":"2014","unstructured":"Mirra M, Di Maio M, Vitulano G et al (2014) Management of atrial fibrillation in patients undergoing percutaneous coronary intervention. Transl Med UniSa 9:33\u201337","journal-title":"Transl Med UniSa"},{"key":"2855_CR29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"2855_CR30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amjmed.2014.02.030","volume":"127","author":"LA Asencio","year":"2014","unstructured":"Asencio LA, Huang JJ, Alpert JS (2014) Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? Am J Med 127:579\u2013585","journal-title":"Am J Med"},{"key":"2855_CR31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS et al (2014) 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1\u2013e76","journal-title":"J Am Coll Cardiol"},{"key":"2855_CR32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJM Dewilde","year":"2013","unstructured":"Dewilde WJM, Oirbans T, Verheugt FWA et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107\u20131115","journal-title":"Lancet"},{"key":"2855_CR33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29\u201338","journal-title":"Lancet"},{"key":"2855_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319","journal-title":"N Engl J Med"},{"issue":"815\u2013821","key":"2855_CR35","first-page":"e6","volume":"161","author":"CM Gibson","year":"2011","unstructured":"Gibson CM, Mega JL, Burton P et al (2011) Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 161(815\u2013821):e6","journal-title":"Am Heart J"},{"key":"2855_CR36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11739-013-1008-9","volume":"8","author":"A Rubboli","year":"2013","unstructured":"Rubboli A, Oldgren J, Mar\u00ecn F, Lip G (2013) Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Intern Emerg Med 8:673\u2013680","journal-title":"Intern Emerg Med"},{"key":"2855_CR37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.03.003","volume":"13","author":"RI Lindley","year":"2004","unstructured":"Lindley RI, Wardlaw JM, Sandercock PAG et al (2004) Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis 13:235\u2013246","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2855_CR38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ageing\/afq110","volume":"39","author":"PD Mudd","year":"2010","unstructured":"Mudd PD, James MA (2010) Anticoagulation for atrial fibrillation: should warfarin be temporarily stopped or continued after acute cardioembolic stroke? Age Ageing 39:670\u2013673","journal-title":"Age Ageing"},{"key":"2855_CR39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(13)70055-3","volume":"12","author":"J \u00c1lvarez-Sab\u00edn","year":"2013","unstructured":"\u00c1lvarez-Sab\u00edn J, Maisterra O, Santamarina E, Kase CS (2013) Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol 12:689\u2013705","journal-title":"Lancet Neurol"},{"key":"2855_CR40","doi-asserted-by":"publisher","first-page":"CD000024","DOI":"10.1002\/14651858.CD000024.pub4","volume":"3","author":"PAG Sandercock","year":"2015","unstructured":"Sandercock PAG, Counsell C, Kane EJ (2015) Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 3:CD000024. doi:\n                        10.1002\/14651858.CD000024.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2855_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/9780470696361","author":"C Warlow","year":"2008","unstructured":"Warlow C, van Gijn J, Dennis M, Wardlaw J, Bamford J, Hankey G, Sandercock P, Rinkel G, Langhorne P, Sudlow C, Rothwell P (2008) Stroke: Practical Management. Third Edit. doi:\n                        10.1002\/9780470696361","journal-title":"Third Edit"},{"key":"2855_CR42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ijs.12158","volume":"9","author":"ER McGrath","year":"2014","unstructured":"McGrath ER, Eikelboom JW, Kapral MK, O\u2019Donnell MJ (2014) Novel oral anticoagulants: a focused review for stroke physicians. Int J Stroke 9:71\u201378","journal-title":"Int J Stroke"},{"key":"2855_CR43","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ, Stevens SR, Piccini JP et al (2014) Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 45:1304\u20131312","journal-title":"Stroke"},{"key":"2855_CR44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1160\/TH14-11-0973","volume":"114","author":"M Cappellari","year":"2015","unstructured":"Cappellari M, Bovi P (2015) Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update. Thromb Haemost 114:440\u2013444","journal-title":"Thromb Haemost"},{"key":"2855_CR45","first-page":"5","volume":"7","author":"S Mehta","year":"2014","unstructured":"Mehta S, Dababneh H, Hussain M et al (2014) Endovascular treatment in acute ischemic stroke patient on factor Xa inhibitor. J Vasc Interv Neurol 7:5\u20137","journal-title":"J Vasc Interv Neurol"},{"key":"2855_CR46","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.015","volume":"23","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ogata T, Fukae J et al (2014) Revascularization for acute ischemic stroke is safe for rivaroxaban users. J Stroke Cerebrovasc Dis 23:e427\u2013e431","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2855_CR47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/CIRCULATIONAHA.115.015484","volume":"132","author":"DJ Seiffge","year":"2015","unstructured":"Seiffge DJ, Hooff R-J, Nolte CH et al (2015) Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation 132:1261\u20131269","journal-title":"Circulation"},{"key":"2855_CR48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00392-013-0560-7","volume":"102","author":"T Steiner","year":"2013","unstructured":"Steiner T, B\u00f6hm M, Dichgans M et al (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 102:399\u2013412","journal-title":"Clin Res Cardiol"},{"key":"2855_CR49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/ijs.12295","volume":"9","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ, Norrving B, Hacke W, Steiner T (2014) Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke 9:627\u2013632","journal-title":"Int J Stroke"},{"issue":"7","key":"2855_CR50","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/ijs.12604","volume":"10","author":"D Toni","year":"2015","unstructured":"Toni D, Mangiafico S, Agostoni E, Bergui M, Cerrato P, Ciccone A, Vallone S, Zini A, Inzitari D (2015) Intravenous thrombolysis and intra-arterial interventions in acute ischemic stroke: Italian Stroke Organisation (ISO)-SPREAD guidelines. Int J Stroke 10(7):1119\u20131129","journal-title":"Int J Stroke"},{"key":"2855_CR51","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","volume":"36","author":"RG Hart","year":"2005","unstructured":"Hart RG, Tonarelli SB, Pearce LA (2005) Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 36:1588\u20131593","journal-title":"Stroke"},{"key":"2855_CR52","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","volume":"26","author":"RG Hart","year":"1995","unstructured":"Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 26:1471\u20131477","journal-title":"Stroke"},{"key":"2855_CR53","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/STROKEAHA.114.005729","volume":"45","author":"S \u00c5sberg","year":"2014","unstructured":"\u00c5sberg S, Eriksson M, Henriksson KM, Ter\u00e9nt A (2014) Warfarin-associated intracerebral hemorrhage after ischemic stroke. Stroke 45:2118\u20132120","journal-title":"Stroke"},{"key":"2855_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000437109","volume":"37","author":"MT Poon","year":"2015","unstructured":"Poon MT, Bell SM, Al-Shahi Salman R (2015) Epidemiology of Intracerebral Haemorrhage. Front Neurol Neurosci. 37:1\u201312","journal-title":". Front Neurol Neurosci."},{"key":"2855_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fneur.2012.00133","volume":"3","author":"A Charidimou","year":"2012","unstructured":"Charidimou A, Shakeshaft C, Werring DJ (2012) Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol 3:133","journal-title":"Front Neurol"},{"key":"2855_CR56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ana.22690","volume":"71","author":"AR Folsom","year":"2012","unstructured":"Folsom AR, Yatsuya H, Mosley TH et al (2012) Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol 71:552\u2013559","journal-title":"Ann Neurol"},{"key":"2855_CR57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1468-1331.2011.03451.x","volume":"19","author":"S Yamada","year":"2012","unstructured":"Yamada S, Saiki M, Satow T et al (2012) Periventricular and deep white matter leukoaraiosis have a closer association with cerebral microbleeds than age. Eur J Neurol 19:98\u2013104","journal-title":"Eur J Neurol"},{"key":"2855_CR58","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.clineuro.2013.03.004","volume":"115","author":"DN Orken","year":"2013","unstructured":"Orken DN, Uysal E, Timer E et al (2013) New cerebral microbleeds in ischemic stroke patients on warfarin treatment: two-year follow-up. Clin Neurol Neurosurg 115:1682\u20131685","journal-title":"Clin Neurol Neurosurg"},{"key":"2855_CR59","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/nan.12062","volume":"40","author":"BM Janaway","year":"2014","unstructured":"Janaway BM, Simpson JE, Hoggard N et al (2014) Brain haemosiderin in older people: pathological evidence for an ischaemic origin of magnetic resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol 40:258\u2013269","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2855_CR60","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/STROKEAHA.114.005430","volume":"45","author":"BJ Connolly","year":"2014","unstructured":"Connolly BJ, Pearce LA, Hart RG (2014) Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. Stroke 45:1672\u20131678","journal-title":"Stroke"},{"issue":"8","key":"2855_CR61","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ajem.2014.04.051","volume":"32","author":"K Hamden","year":"2014","unstructured":"Hamden K, Agresti D, Jeanmonod R, Woods D, Reiter M, Jeanmonod D (2014) Characteristics of elderly fall patients with baseline mental status: high-risk features for intracranial injury. Am J Emerg Med 32(8):890\u2013894","journal-title":"Am J Emerg Med"},{"key":"2855_CR62","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(14)70015-8","volume":"13","author":"RD Brown","year":"2014","unstructured":"Brown RD, Broderick JP (2014) Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol 13:393\u2013404","journal-title":"Lancet Neurol"},{"key":"2855_CR63","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/14656566.2013.773310","volume":"14","author":"G Palareti","year":"2013","unstructured":"Palareti G, Ageno W, Ferrari A et al (2013) Clinical management of rivaroxaban-treated patients. Expert Opin Pharmacother 14:655\u2013667","journal-title":"Expert Opin Pharmacother"},{"key":"2855_CR64","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093\u20131100","journal-title":"Chest"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-017-2855-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-017-2855-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-017-2855-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T11:09:40Z","timestamp":1495537780000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-017-2855-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,25]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2855"],"URL":"https:\/\/doi.org\/10.1007\/s10072-017-2855-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,25]]}}}